Free standard shipping on orders $300+ · Same-day dispatch before 2PM AEST
AUSTRALIAN OWNED & OPERATED
FAST DISCREET SHIPPING AUSTRALIA WIDE
LAB TESTED FOR PURITY & QUALITY
Customer Support:
contact@aussiepeptideco.com
Packaging Notice: Vial label design and print may vary between batches. Product specifications remain unchanged.
Growth Hormone Research

Tesamorelin

Stabilised GHRH analogue (trans-3-hexenoyl-GRF 1-44)

Be the first to review SKU: APC-TESAMORELIN-5MG
Purity≥99.0% by HPLC
Independently TestedThird-Party Analysis
Batch-Specific COAAvailable for This Batch
$76.00 AUD
In Stock
Strength
Quantity
Order before 2PM AEST for same-day dispatch.

Related Laboratory Supplies

Essential items for laboratory research and sample preparation.

Third-Party Tested

HPLC Purity & Mass Spec Identity

Batch-Specific COA

Certificate for Each Batch

Discreet Packaging

Plain, Unbranded & Tamper-Evident

Same-Day Dispatch

Order Before 2PM AEST, Australia-Wide

Tesamorelin is a synthetic peptide that acts as a growth hormone-releasing hormone (GHRH) receptor agonist. It is studied for its role in growth hormone signalling, pituitary receptor activity and related metabolic pathways. Tesamorelin Australia research includes investigations into peptide–receptor interactions, intracellular signalling and the regulation of growth hormone secretion.

The Tesamorelin material described on this page is intended strictly for laboratory and scientific research, not for human or veterinary use.

What Is Tesamorelin?

Tesamorelin is a synthetic analogue of human growth hormone-releasing hormone (GHRH). It contains 44 amino acids and has a modified N-terminal structure designed to improve resistance to enzymatic degradation compared with native GHRH.

The peptide interacts with GHRH receptors, which are involved in regulating growth hormone release from the anterior pituitary gland.

Tesamorelin has been investigated in clinical and experimental research involving growth hormone regulation, insulin-like growth factor 1 (IGF-1) signalling and metabolic function.

The pharmaceutical form of tesamorelin is distinct from independently supplied research material. Laboratory-grade Tesamorelin is not automatically equivalent to an approved medicine, regardless of whether the same active molecular structure is present.

Tesamorelin in Endocrine and Metabolic Research

Tesamorelin has been examined in published studies involving growth hormone regulation, IGF-1 responses and changes in metabolic parameters.

Research areas include pituitary receptor signalling, endocrine feedback mechanisms, lipid metabolism and the relationship between growth hormone activity and metabolic function.

Clinical investigations have also examined pharmaceutical tesamorelin in specific patient populations. Findings from those studies relate to the tested pharmaceutical formulation and study conditions.

Laboratory research may use receptor-based assays, cellular models or other validated experimental systems to investigate particular signalling mechanisms.

Results from clinical studies should not be interpreted as evidence of safety or effectiveness for independently supplied research material.

Quick Product Information

Specification Details
Product name Tesamorelin
Research classification Synthetic GHRH analogue
Research targets GHRH receptor (GHRHR)
Molecular formula C₂₂₁H₃₆₆N₇₂O₆₇S
Molecular weight Approximately 5,135.9 g/mol
CAS number 218949-48-5
Physical form Lyophilised powder, subject to product documentation
Available strengths 5mg, 10mg and 20mg
Purity Refer to verified batch-specific analytical results
Analytical testing methods HPLC and MS, where documented
Certificate of Analysis Batch-specific CoA, where available
Storage requirements Follow verified product-specific storage documentation
Intended use Laboratory and in-vitro research only

How Tesamorelin Works in Research

GHRH Receptor Activity

Tesamorelin interacts with the growth hormone-releasing hormone receptor, a G protein-coupled receptor associated with pituitary growth hormone regulation.

Receptor activation stimulates intracellular signalling involving cyclic adenosine monophosphate (cAMP) and protein kinase A (PKA).

These signalling processes are relevant to investigations of growth hormone secretion, receptor responsiveness and endocrine regulation.

Growth Hormone and IGF-1 Signalling

Growth hormone participates in several physiological pathways, including those associated with protein metabolism, lipid regulation and cellular growth.

In established physiological models, growth hormone also influences IGF-1 production, particularly through hepatic signalling.

Researchers study these connected pathways to understand endocrine feedback, receptor activation and metabolic regulation.

Tesamorelin provides a defined GHRH receptor agonist for investigating these mechanisms under controlled experimental conditions.

Tesamorelin vs Other Growth Hormone Research Peptides

Different research peptides influence the growth hormone pathway through distinct mechanisms.

Compound Primary receptor activity
Tesamorelin GHRH receptor agonist
Sermorelin GHRH receptor agonist
CJC-1295 GHRH receptor agonist
Ipamorelin Ghrelin receptor (GHSR1a) agonist

Tesamorelin and Sermorelin act through the GHRH receptor but differ in peptide structure. Ipamorelin interacts with the ghrelin receptor instead. CJC-1295 variants also differ in their molecular modifications and pharmacological characteristics.

Tesamorelin Research in Australia

Australian laboratories working with Tesamorelin should maintain appropriate documentation covering material identity, batch traceability, analytical testing and intended research use.

The Therapeutic Goods Administration (TGA) regulates therapeutic goods supplied in Australia. Regulatory requirements depend on the product’s classification, intended purpose and supply circumstances.

Research-only Tesamorelin must not be represented as a TGA-approved therapeutic product without specific regulatory authorisation.

Laboratories should also consider applicable institutional requirements, import conditions and chemical handling procedures.

Batch identification and supporting analytical records help researchers maintain consistency and traceability across experimental work.

This product is intended strictly for laboratory and in-vitro research purposes. It has not been evaluated for human or veterinary use, and any information provided here is for educational reference only.

Specifications

Product NameTesamorelin 5mg
ManufacturerZynova Labs
Strength5mg
Molecular FormulaC₂₂₁H₃₆₆N₇₂O₆₇S
Molecular Weight5,135.9 g/mol
Purity≥99.0% (HPLC, batch ZL-31-5)
CAS No.218949-48-5
FormLyophilised powder, subject to product documentation
StorageFollow verified product-specific storage documentation
Research CategoryGrowth Hormone Research
TestingIndependent third-party HPLC & MS
DocumentationBatch-specific COA included
UsageFor Research Use Only. Not for human consumption.

Certificate of Analysis

Quality, Purity and Batch Testing

Analytical testing helps establish whether a research peptide has the expected molecular identity and composition.

High-Performance Liquid Chromatography (HPLC) separates components within a sample and can support analytical purity assessment.

Mass Spectrometry (MS) measures mass-to-charge ratios and provides evidence relevant to molecular identity. LC-MS combines chromatographic separation with mass analysis.

A batch-specific Certificate of Analysis (CoA) should identify the material, batch reference, testing methods and reported results.

Actual purity values and test outcomes must be taken from verified batch documentation.

Analytical purity does not establish sterility, absence of endotoxins, clinical safety or suitability for human administration.

CERTIFICATE OF ANALYSIS
Tesamorelin 5mg
Batch: ZL-31-5 · 18/05/2026
Janoshik Analytical Certificate of Analysis for Tesamorelin 5mg

Storage & Handling

Storage and Laboratory Handling

Tesamorelin research material should be stored according to the conditions specified in its verified product and batch documentation.

Laboratories should manage temperature exposure, moisture, light and container integrity according to the material’s documented requirements.

Appropriate contamination controls, sample labelling and standard operating procedures should be followed during handling.

Storage duration and stability after reconstitution should not be assumed without supporting formulation-specific stability data.

Research Use Disclaimer: For Research Use Only. Not for human or veterinary use. This material is intended strictly for laboratory and in-vitro research purposes and must not be consumed or administered.

Unopened VialFollow verified product-specific storage documentation
HandlingUse appropriate PPE and standard laboratory safety procedures
ShippingTracked, discreet delivery Australia-wide via Australia Post. Express available.

Reconstitution calculator: Tesamorelin 5mg

Work out concentration and the volume to draw for each aliquot before you add diluent.

mg
mL
Concentration
–
Volume per aliquot
–
On a 1 mL (U-100) syringe
–
Aliquots per vial
–

A laboratory arithmetic aid only. Verify every calculation independently. Not dosing guidance; research use only.

For Research Use Only. Not for human or veterinary consumption.

Tesamorelin Frequently Asked Questions

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone. It interacts with GHRH receptors and is studied for its involvement in growth hormone regulation and related endocrine signalling pathways.

Tesamorelin is a modified 44-amino-acid peptide classified as a GHRH analogue. Its structure includes an N-terminal modification that increases resistance to certain enzymatic degradation processes.

Tesamorelin primarily targets the growth hormone-releasing hormone receptor (GHRHR). This receptor is associated with pituitary growth hormone secretion and intracellular signalling through the cAMP-dependent pathway.

Both peptides act on GHRH receptors. Tesamorelin contains 44 amino acids and an N-terminal modification, while Sermorelin contains the first 29 amino acids of native human GHRH.

Tesamorelin activates GHRH receptors, whereas Ipamorelin acts through ghrelin receptors. These distinct receptor targets allow researchers to investigate different signalling mechanisms associated with growth hormone regulation.

Researchers investigate Tesamorelin to understand growth hormone signalling, IGF-1 responses, lipid metabolism and endocrine feedback. Published findings depend on the experimental model, formulation and study conditions.

The molecular formula of Tesamorelin's free peptide is C₂₂₁H₃₆₆N₇₂O₆₇S, with a molecular weight of approximately 5,135.9 g/mol. Salt forms may have additional components.

HPLC can assess the relative abundance of chromatographically separated components. Mass spectrometry provides supporting molecular identity information. Reported purity must be linked to a specific tested batch.

A CoA should identify the peptide, batch number, analytical methods, testing dates, specifications and results. Relevant chromatographic and mass spectrometric data may support identity and purity assessment.

No. This Tesamorelin material is intended exclusively for laboratory and in-vitro research. It is not a therapeutic medicine and must not be consumed or administered to humans or animals.

No. This product is supplied strictly for in-vitro laboratory research. It is not approved for human or veterinary use and must not be consumed or administered.

Orders placed before 2PM AEST on business days are dispatched the same day from Melbourne. Standard Post takes 3–7 business days and Express Post 1–3 business days, both tracked and discreet.

Reviews

There are no reviews yet.

Be the first to review “Tesamorelin”

Your email address will not be published. Required fields are marked *

Shopping Cart (0 items)

Your cart is empty

Add some research compounds to get started.

Browse Products